ArticleBMC nephrology2025
Effects of different peritoneal dialysis solutions on serum lipid levels and lipid profile in end-stage chronic kidney disease patients undergoing peritoneal dialysis.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association of Serial Intra-Abdominal Pressure Measurements with Renal Outcomes and Mortality in Critically Ill Adults.Journal of clinical medicine · 2026Article
- Lipid Disorders in Patients with Renal Failure: Role in Cardiovascular Events and Progression of Chronic Kidney Disease.Life (Basel, Switzerland) · 2026Review
- Lipoprotein Combine Index Is Associated with Multi-Compartment Oxidative Stress in Clinically Stable Peritoneal Dialysis Patients: A Cross-Sectional Study.Biomedicines · 2026Article
- Pre-existing cardiovascular disease and hyperlipidemia and mortality in peritoneal dialysis patients.Frontiers in endocrinology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular diseases are the leading causes of morbidity and mortality in patients undergoing peritoneal dialysis and hemodialysis due to end-stage renal disease. Dyslipidemia is a major contributing factor to the development of atherosclerotic cardiovascular diseases, and its prevention is recommended to reduce cardiovascular risk. Several studies have demonstrated the presence of dyslipidemia in patients with chronic kidney disease, and peritoneal dialysis patients have been observed to have a more atherogenic lipid profile compared to those receiving hemodialysis. One of the primary reasons for this is thought to be the absorption of glucose from peritoneal dialysis solutions. In this study, we aimed to assess dyslipidemia in peritoneal dialysis patients and investigate the relationship between glucose absorption from dialysis solutions and lipid profile alterations. A total of 73 patients followed up in the nephrology outpatient clinic were included. Patients’ lipid profiles, the types of dialysis solutions used, and their compositions were statistically analyzed. A statistically significant inverse correlation was found between the amount of glucose absorbed during peritoneal dialysis and HDL cholesterol levels, which was observed both in the overall peritoneal dialysis patient group and in the subgroup undergoing automated peritoneal dialysis (APD). However, no statistically significant relationship was found between glucose absorption and other lipid parameters. Our findings suggest that the glucose content of peritoneal dialysis solutions alone does not play a major role in the development of dyslipidemia when considering all atherogenic lipid parameters. Therefore, dyslipidemia in peritoneal dialysis patients should be evaluated by considering all contributing factors, including treatment-related effects and, in particular, the structural and functional characteristics of the peritoneal membrane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.